The Insiders Fund, LP on Boston Scientific Corporation
Thesis
The Insiders Fund sees Boston Scientific as a potential longer-term beneficiary of aging populations and sustained demand for medical technologies. Its cardiology, electrophysiology and other minimally invasive devices address substantial clinical needs. The manager points to major purchases by insiders, including a roughly $9 million purchase by the CEO, and institutional support as reasons to expect eventual upside. The investment remains exposed to near-term disruption from an August cyberattack, guidance pressure and product recalls, but operations were reported to have been restored by mid-September.
“significant insider buying (including the CEO purchasing over $9 million in stock) and strong institutional support suggest potential upside for long-term investors.”
Key risks
- An August 2026 cyberattack disrupted global shipping, manufacturing and operations
- Management warned it would miss full-year net sales and earnings guidance
- Medical device recalls and FDA actions
- Slower growth in Watchman and electrophysiology